Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
about
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and ChangesCorrelation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinomaImpact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomyc-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report.The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostaImmunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group.Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.New findings on thymic epithelial tumors: Something is changing.Rare frequency of gene variation and survival analysis in thymic epithelial tumors.Rare Case of Spinal Cord Compression as Initial Presentation of Thymic Carcinoma.Novel Agents in the Treatment of Thymic Malignancies.Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker.Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.The Integrated Genomic Landscape of Thymic Epithelial Tumors.[Thymomas].Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma.Metastatic Thymic Carcinoma with Long Survival After Treatment with SunitinibThe genomic and epigenomic landscape in thymic carcinoma
P2860
Q28087370-3ABB3F78-39FD-4CD9-B064-5D095B32C2A4Q35936010-9E8631BE-BFC8-4252-A92D-1F1268225E9CQ36326385-2796DC6C-0265-4797-BA63-DCEC04BF2219Q36741396-D3396088-6EF1-4C09-832E-219649FF45CEQ37477372-AC711154-7AFE-49BA-88EB-031BAC0C8D9FQ37705851-151F506A-2B8F-4280-90E4-46E5F66CD74DQ37711931-501D3085-27B3-4FB9-88CA-D9C4784FD3C8Q38627885-E053A45B-F9E9-4183-8B9E-29386AD21524Q38662451-423160D4-613F-4DF4-9FEB-4BA2CA1E2803Q39162064-3A4C67D2-0A7C-4FA7-ACE7-87FF1A270375Q39239578-515AEF67-0359-4AE1-A7AA-7C730BB6207AQ40096396-947D77E3-E533-4DF5-914C-BE07F46A7590Q40430354-9F4783F2-772F-4E69-8E1F-8D28C6C120DCQ41518202-3DCE2192-7CFA-48F8-8A60-3CFE914A9CD5Q45234027-589D102C-B1EF-4B34-9676-C4BBA5FDADEEQ48696917-169B403F-6667-49AF-AA95-320ECC6909C2Q49497914-AA085B00-60EF-4D39-8FA0-BDA01E1DAAFEQ49643762-EF441CCC-AC72-4D67-9DE7-50D234986076Q50040409-0BB8FBBB-30E2-475A-BEFF-2B269221F00EQ52955529-B414FD2F-9A38-4661-8633-533185813376Q54119194-672C158D-E6A8-4BF7-A434-787B04F06ABCQ57652304-B6F7C2AD-90AC-4788-A9DE-BC6A4781E6A5Q57700809-FFA7CF42-FAA6-49BB-80FD-1BDD96C49ADD
P2860
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@ast
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@en
type
label
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@ast
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@en
prefLabel
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@ast
Sunitinib in patients with che ...... : an open-label phase 2 trial.
@en
P2093
P2860
P50
P1433
P1476
Sunitinib in patients with che ...... a: an open-label phase 2 trial
@en
P2093
Aaron J Spittler
Alexander Ling
Arlene Berman
Arun Rajan
Christina Brzezniak
Corey A Carter
Jane B Trepel
Min-Jung Lee
Patrick J Loehrer
Paul Meltzer
P2860
P304
P356
10.1016/S1470-2045(14)71181-7
P577
2015-01-13T00:00:00Z